Joshua Brumm has been appointed president and CEO of Dyne Therapeutics. Romesh Subramanian, Dyne’s founder and former CEO, has shifted to a new role as chief scientific officer. Brumm will join Waltham, MA-based Dyne from Kaleido Biosciences (NASDAQ: KLDO), where he has been chief financial officer since last year. Kaleido said Brumm’s last day will be Oct. 11. Dyne, which is developing antibody drugs to treat rare muscular disorders, closed $50 million in Series A financing in April.